The inhibitors of Glo1 (TLSC702) and PKCλ (aurothiomalate) emerge as potential pharmacological approaches to manage late-stage breast cancer by suppressing cell viability and tumor-sphere formation [102]. The gene discussed is GLO1; the disease is neoplasm.